A fair share for the orphans: Ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation

Journal of Medical Ethics

Volumn 38, Issue 3, 2012, Pages 148-153

  Pinxten, Wim ^a   Denier, Yvonne ^b   Dooms, Marc ^c   Cassiman, Jean Jacques ^b   Dierickx, Kris ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOETHICS; DRUG MANUFACTURE; ECONOMICS; EUROPE; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; MORALITY; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; RARE DISEASE; RESEARCH; RESOURCE ALLOCATION;

BIOETHICS; ETHICS, MEDICAL; EUROPE; GUIDELINES AS TOPIC; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; MORALS; ORPHAN DRUG PRODUCTION; RARE DISEASES; RESEARCH; RESEARCH SUPPORT AS TOPIC; RESOURCE ALLOCATION;

EID: 84860431228     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/medethics-2011-100094     Document Type: Article

References (25)

1. Orphanet. http://www.orpha.net/consor/cgi-bin/index.php (accessed 1 Oct 2010).
2. Stolk P, Willemen MJ, Leufkens HG. Rare essentials: drugs for rare diseases as essential medicines. Bull World Health Organ 2006;84:745-51.
3. Fernandez CV. Our moral obligations in caring for patients with orphan cancers. CMAJ 2007;176:297, 99.
4. van Weely S, Leufkens HG. Orphan Diseases. In: Kaplan W, Laign R, eds. Priority Medicines for Europe and the World Project: A public health approach to innovation. Geneva: World Health Organization, 2004.
5. Stakisaitis D, Spokiene I, Juskevicius J, et al. Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: the EuOrphan Service. Medicina (Kaunas) 2007;43:441-6.
6. Bosquanet N, Domenighetti G, Beresniak A, et al. Equity, access and economic evaluation in rare diseases. The impact of orphan drug legislation on health policy and patient care. Pharm Dev Regul 2003;1:151-7.
7. Register of Designated Orphan Medicinal Products http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm, (accessed 6 Apr 2011).
8. Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics 2005;31:164-8.
9. Denier Y. Efficiency, Justice and Care. Philosophical Reflections on Scarcity in Health Care. Dordrecht: Springer, 2007.
10. Daniels N. Just Health Care. Cambridge: Cambridge University Press, 1985.
11. Callahan D. The WHO definition of 'health'. Stud Hastings Cent 1973;1:77-88.
12. Callahan D. What Kind of Life? The limits of Medical Progress. Washington: Georgetown University Press, 1990.
13. Denier Y. Mind the gap!Three approaches to scarcity in health care. Med Health Care and Philos 2008;11:73-87.
14. Landman WA, Henley LD. Equitable rationing of highly specialised health care services for children: a perspective from South Africa. J Med Ethics 1999;25:224-9.
15. Reidenberg MM. Are drugs for rare diseases "essential"? Bull World Health Organ 2006;84:686.
16. Schieppati A, Henter JI, Daina E, et al. Why rare diseases are an important medical and social issue. Lancet 2008;371:2039-41.
17. http://www.who.int (accessed 1 Jul 2010).
18. McCabe C, Tsuchiya A, Claxton K, et al. Orphan drugs revisited. QJM 2006;99:341e5; discussion 50-1.
19. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 2005;98:829-36.
20. Campos-Castello J, Ponsot G, Feillet F, et al. Orphan drugs and orphan diseases. Round table proceedings, 3rd European Pediatric Neurology Society Congress. Nice, November 1999. Eur J Paediatr Neurol 2000;4:141-9.
21. Moors E, Faber J. Orphan drugs: Unmet societal need for non-profitable privately supplied new products. Research Policy 2007;36:336-54.
22. Heemstra HE, de Vrueh RL, van Weely S, et al. Predictors of orphan drug approval in the European Union. Eur J Clin Pharmacol 2008;64:545-52.
23. NICE Proposal for the Appraisal of Orphan Drugs. http://www.nice.org.uk/niceMedia/pdf/smt/120705item4.pdf (accessed 1 Oct 2010).
24. Vanlaere L, Gastmans C. A normative approach to care ethics: the contribution of the Louvain tradition of Personalism. In: Gastmans C, Dierickx K, Nys H, Schotsmans P, eds. New Pathways for European Bioethics. Antwerpen-Oxford: Intersentia, 2007:99-118.
25. Petrini C, Gainotti S. A personalist approach to public-health ethics. Bull World Health Organ 2008;86:624-9.